Full history for every metric is available with a Kvantra account
Hcmed (6934.TWO)
Key financial summary
Financials in TWD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | - | 32 | 54 | 6 | 9 | 142 | 146 |
| Operating profit | TWD m | -38 | -137 | |||||
| Net profit | TWD m | - | -62 | -40 | -144 | -166 | -78 | -143 |
| EPS reported | TWD | -2.59 | -4.52 | |||||
| Operating cashflow per share | TWD | -1.08 | -3.18 | |||||
| Capex per share | TWD | 0.38 | 1.60 | |||||
| FCF per share | TWD | -1.45 | -4.77 | |||||
| Free cash flow | TWD m | -44 | -144 | |||||
| Net debt | TWD m | -176 | -191 | |||||
| Book value equity | TWD m | 209 | 267 | |||||
| Book value per share | TWD | 6.93 | 8.12 | |||||
| Number of shares | m | 30.2 | 32.85 | |||||
| DPS (TTM paid) | TWD | 0.00 | 0.00 |
Financial summary
Financials in TWD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 11.93 | 20.90 | |||||
| P/S LTM | x | 17.64 | 38.20 | |||||
| P/FCF LTM | x | -56.85 | -38.60 | |||||
| EV/EBITDA LTM | x | -91.77 | -64.60 | |||||
| EV/Sales LTM | x | 17.24 | 36.89 | |||||
| Earnings Yield LTM | % | -3.13% | -2.61% | |||||
| FCF Yield | % | -1.76% | -2.59% | |||||
| Quality | ||||||||
| ROE | % | -37.37% | -46.08% | |||||
| ROIC | % | -16.53% | -50.79% | |||||
| Operating margin | % | -26.55% | -729.08% | |||||
| Gross margin | % | 70.37% | -123.61% | |||||
| FCF/Sales | % | -31.02% | -676.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +1433.4% | +177.71% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.97 | -2.27 | |||||
| Net Debt/EBITDA | x | 2.14 | -0.33 | |||||
| EBIT/Net interest | x | -156.66 | -175.14 | |||||
| Net debt/market cap | % | -7.04% | -3.43% | |||||
| Net debt/Equity | x | -0.84 | -0.72 | |||||
| Gross debt/equity | x | 0.04 | 0.24 | |||||
Company overview
HCmed Innovations Co Ltd. specializes in creating advanced solutions for respiratory treatment through the application of mesh technology. Their product line features devices such as Pulmogine and AdheResp. Beyond its core offerings, the company delivers extensive analytical services focused on aerosol characterization, helping clients optimize and develop new inhaled therapeutic products. This analytical assistance is provided in strict adherence to Pharmacopoeia standards. Founded on October 6, 2014, by Jason Cheng, Leon Tsai, Shaogi Huang, and Simon Hsieh, HCmed maintains its principal office in Taipei, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hcmed (6934.TWO)
HCmed Innovations Co Ltd. specializes in creating advanced solutions for respiratory treatment through the application of mesh technology. Their product line features devices such as Pulmogine and AdheResp. Beyond its core offerings, the company delivers extensive analytical services focused on aerosol characterization, helping clients optimize and develop new inhaled therapeutic products. This analytical assistance is provided in strict adherence to Pharmacopoeia standards. Founded on October 6, 2014, by Jason Cheng, Leon Tsai, Shaogi Huang, and Simon Hsieh, HCmed maintains its principal office in Taipei, Taiwan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free